EMEA-001157-PIP01-11-M02

Table of contents

Key facts

Active substance
Caplacizumab
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0294/2018
PIP number
EMEA-001157-PIP01-11-M02
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of thrombotic thrombocytopenic purpura (TTP)
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Ablynx NV

E-mail: bernard.delaey@ablynx.com
Tel. +32 2620 000

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-001157-PIP01-11-M02
Compliance opinion date
23/08/2019
Compliance outcome
positive

Decision

How useful was this page?

Add your rating